HOME    |    CBD RESEARCH    |    FAQ    |    ABOUT US    |    CONTACT US    |    PROFESSIONAL

NeuOra CBD
& The Latest 
CBD Research

Cannabinoids as Antioxidants and Neuroprotectants

US Department of Health and Human Services (HHS)

Aidan J. Hampson, Julius Axelrod, Maurizio Grimaldi

Patent Application # US6630507B1

 

Clinicians' Guide to Cannabidiol and Hemp Oils.

VanDolah HJ, Bauer BA, Mauck KF. Mayo Clin Proc. 2019 Jun 12.  (Full text)

 

 

Drug Absorption.

PharmD, MAS, BCPS-ID, FIDSA, FCCP, FCSHP, Skaggs School of

Pharmacy and Pharmaceutical Sciences, University of California San Diego 2019

 

 

Buccal Mucosa As A Route For Systemic Drug Delivery: A Review.
Amir H Shojaei, Faculty of Pharmacy and Pharmaceutical Sciences,

University of Alberta, Edmonton

 

 

Understanding  Oral Mucosal Absorption.

PJeremy A. Bartlett and Kees van der Voort Maarschalk 2019

 

 

Oral Mucosal Drug Delivery Clinical Pharmacokinetics and
Therapeutic Applications.

Hao Zhang,1 Jie Zhang2and James B. Streisan

 

 

Medical Marijuana and Chronic Pain: a Review of Basic

Science and Clinical Evidence.

Jensen B, et al. Curr Pain Headache Rep. 2015

 

 

Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

Eric P. Baron, Philippe Lucas, Joshua Eades, Olivia Hogue

J Headache Pain. 2018

 

 

Chronic Pain Patients’ Perspectives of Medical Cannabis

Brian J Piper, Monica L Beals, Alexander T Abess, Stephanie D Nichols,

Maurice Martin, Catherine M. Cobb, Rebecca M DeKeuster

Author manuscript; available in PMC 2018

 

 

Cannabis-based medicines for chronic neuropathic pain in adults.

Mücke M, et al. Cochrane Database Syst Rev. 2018

 

 

Cannabinoids for fibromyalgia.

Walitt B, et al. Cochrane Database Syst Rev. 2016.

 

 

A selective review of medical cannabis in cancer pain management.

Blake A, et al. Ann Palliat Med. 2017

 

 

Multiple mechanisms involved in the large-spectrum therapeutic

potential of cannabidiol in psychiatric disorders.

Campos AC, et al. Philos Trans R Soc Lond B Biol Sci. 2012.

 

 

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.

Franco V, et al. Drugs. 2019

 

 

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.

Millar SA, et al. Front Pharmacol. 2018 (Full text)

 

 

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Randomized controlled trial.

Stott CG, et al. Eur J Clin Pharmacol. 2013

 

 

Exogenous cannabinoids as substrates, inhibitors, and inducers of

human drug metabolizing enzymes: a systematic review.

Stout SM, Cimino NM. Drug Metab Rev. 2014 Feb.

 

 

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Clinical trial.

Stott CG, et al. Eur J Clin Pharmacol. 2013

 

 

Cannabidiol bioavailability after nasal and transdermal application:

effect of permeation enhancers.

Paudel KS, et al. Drug Dev Ind Pharm. 2010

The therapeutic role of cannabinoid receptors and its agonists

or antagonists in Parkinson's disease.

Han QW, Yuan YH, Chen NH. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug . (Full text)

 

 

Pharmacokinetics and tolerability of oral cannabis preparations in

patients with medication overuse headache (MOH)-a pilot study.

Pellesi L, et al. Eur J Clin Pharmacol. 2018

 

 

PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.

Atsmon J, et al. J Pharm Sci. 2018

 

 

Development of Standard Operating Protocols for the Optimization

of Cannabis-Based Formulations for Medical Purposes.

Baratta F, et al. Front Pharmacol. 2019 (Full text)

 

 

Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol.

Mannila J, et al. J Pharm Sci. 2007

 

 

Effects of RM-beta-CD on sublingual bioavailability of Delta9-

tetrahydrocannabinol in rabbits.

Mannila J, et al. Eur J Pharm Sci. 2005

 

 

Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.

Reuter SE, et al. Clin Pharmacokinet. 2016

 

 

Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient

with metastatic low grade serous ovarian carcinoma.

Barrie AM, et al. Gynecol Oncol Rep. 2019

 

 

Inhibition of colon carcinogenesis by a standardized Cannabis

sativa extract with high content of cannabidiol.

Romano, Borrelli F2, Pagano, Cascio, Pertwee, Izzo  Phytomedicine. 2014

 

 

Role of the endocannabinoidome in human and mouse atherosclerosis.

Piscitelli F, Silvestri C. Curr Pharm Des. 2019 Aug 26. doi: 10.217

 

 

 

Cannabidiol displays unexpectedly high potency as an antagonist

of CB1 and CB2 receptor agonists in vitro.

Thomas, Baillie Phillips,  Razdan. Ross, Pertwee R, Br J Pharmacol. 2007 Mar

 

 

Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.

Pietrafusa N, et al. Paediatr Drugs. 2019 (

 

 

Use of cannabidiol oil in children.

Wolff D, et al. Ned Tijdschr Geneeskd. 2019.

 

 

Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions

in a Mouse Model of Mild Traumatic Brain Injury.

Belardo C, et al. Front Pharmacol. 2019 (Full text)

 

 

Real life Experience of Medical Cannabis Treatment in Autism:

Analysis of Safety and Efficacy.

Bar-Lev Schleider L, et al. Sci Rep. 2019 (Full text)

 

 

Self-management strategies amongst Australian women with

endometriosis: a national online survey.

Armour M, et al. BMC Complement Altern Med. 2019  (Full text)

 

 

Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. Randomized controlled trial.

Libzon S, et al. J Child Neurol. 2018

 

 

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products.

Meng Q, et al. PLoS One. 2018